Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0522 • ACR Convergence 2020
Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase III Case Collection Results
Medha Barbhaiya¹, Stephane Zuily², Yasaman Ahmadzadeh³, Karen Costenbader⁴, Raymond Naden⁵ and Doruk Erkan⁶, ¹Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, ²Nancy Academic Hospital, Vandoeuvre-l�Nancy, France, ³Hospital for Special Surgery, New York, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Department of Medicine, Middlemore Hospital, Auckland, Auckland, New Zealand, ⁶Hospital for Special Surgery, New York, NY
Background/Purpose: An international multi-disciplinary effort is underway to develop rigorous, new, consensus- and evidence-based classification criteria for Antiphospholipid Syndrome (APS). The methodological approach includes four…
Abstract Number: 1451 • ACR Convergence 2020
Longitudinal Assessment of Anti-beta 2 Glycoprotein in SLE
Michelle Petri¹, Laurence Magder² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Although anti-beta2 glycoprotein is one of the three antiphospholipid antibodies recognized in the Sydney APS classification criteria, it is one of the least studied. …
Abstract Number: 0523 • ACR Convergence 2020
Characterization of Antiphospholipid Antibody-Associated Nephropathy: An International Survey of Renal Pathology Society Members
Medha Barbhaiya¹, Doruk Erkan², Stephane Zuily³, Tektonidou Maria⁴ and Surya Seshan⁵, ¹Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Nancy Academic Hospital, Vandoeuvre-l�Nancy, France, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Weill Cornell Medical College, New York, NY
Background/Purpose: Antiphospholipid antibody (aPL)-associated nephropathy (aPL-N) is recognized as a distinct complication of APS. However, it remains unclear whether pathologists worldwide use uniform diagnostic criteria…
Abstract Number: 1501 • ACR Convergence 2020
Obstetrical Outcome and Thromboses in a Multicentric Cohort of Antiphospholipid Syndrome (APS) Patients with Severe Preeclampsia: An Analysis of APS Classification Criteria
Maddalena Larosa¹, Nathalie Morel², Meriem Belhocine³, Amelia Ruffatti⁴, Nicolas Martin Silva⁵, Romain Paule⁶, Luc Mouthon⁷, Michel Dreyfus⁸, Jean-Charles Piette⁹, Odile Souchaud-Debouverie¹⁰, Catherine Deneux-Tharaux¹¹, Vassilis Tsatsaris¹², Emmanuelle Pannier Metzger¹³, Gaëlle Guettrot-Imbert¹⁴, Veronique Le Guern¹⁵, Andrea Doria¹⁶ and Nathalie Costedoat-Chalumeau¹⁷, ¹Rheumatology Unit-Department of Medicine-University of Padova, Italy, Padova, Veneto, Italy, ²AP-HP, université René-Descartes Paris V, hôpital Cochin, centre de référence maladies auto-immunes et systémiques rares, pôle médecine, service de médecine interne, Paris, France., Paris, Ile-de-France, France, ³Hôpital Sacré-Coeur de Montréal , Montréal, Montreal, QC, Canada, ⁴Department of Medicine, University of Padova, Padova, Veneto, Italy, ⁵Centre Hospitalier et Universitaire de Caen, Caen, France, ⁶Foch Hospital, Paris, France, ⁷Hopital Cochin - Paris University, Paris, France, ⁸CHU de Caen, Caen, France, ⁹Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ¹⁰CENTRE HOSPITALIER UNIVERSITAIRE LA MILETRIE, poitiers, France, ¹¹INSERM U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité , Paris Descartes University , Paris , France, Paris, France, ¹²Maternité Port-Royal,Hôpital Cochin, Paris, France, Paris, France, ¹³Maternité Port-Royal,Hôpital Cochin, Paris, France, ¹⁴Médecine Interne,Hôpital Cochin, paris, France, ¹⁵Médecine Interne,Hôpital Cochin, Paris, France, Paris, France, ¹⁶University of Padua, Padua, Italy, ¹⁷APHP, Université de Paris, Paris, France
Background/Purpose: According to APS classification criteria1, clinical manifestations of antiphospholipid syndrome (APS) consist in thrombotic and obstetric events, including severe preeclampsia (PE). Because little is…
Abstract Number: 0524 • ACR Convergence 2020
Determination of Homogenous Subgroups of Antiphospholipid Syndrome: A Cluster Analysis Based on 509 Cases
Yann Nguyen¹, Cécile Yelnik², Nathalie Morel³, Romain Paule⁴, Pierre-Yves Hatron², Romain Stammler⁵, Léo Plaçais³, Jean-Charles Piette⁶, Luc Mouthon⁷, Eric Hachulla⁸, Marc Lambert², Le Guern Véronique³ and Nathalie Costedoat-Chalumeau⁹, ¹1Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, ²Department of Internal Medicine and Clinical Immunology, National Referral Centre for rare Systemic Auto-immune Diseases North and North-West of France (CeRAINO), CHU Lille, Hôpital Claude Huriez, Lille, France, Lille, France, ³National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, France, ⁴Department of Internal Medicine, Hôpital Foch, Suresnes, France, Suresnes, France, ⁵National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, ⁶Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ⁸Department of Internal Medicine and Clinical Immunology, Université de Lille, Lille, France, Lille, France, ⁹APHP, Université de Paris, Paris, France
Background/Purpose: Antiphospholipid syndrome (APS) is a heterogeneous disease, with different phenotypes which may widely vary from classical thrombotic or obstetrical manifestations to catastrophic antiphospholipid syndrome…
Abstract Number: 1680 • ACR Convergence 2020
Lupus Anticoagulant as a Predictor of Adverse Outcomes in Children with Venous Thromboembolism
Elizabeth Sloan¹ and Ayesha Zia¹, ¹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The presence of antiphospholipid antibodies, including lupus anticoagulant (LA), is a risk factor for development of venous thromboembolism (VTE) in children. The impact of…
Abstract Number: 0525 • ACR Convergence 2020
Epidemiology of Thromboembolic Complications Among Hospitalized Patients with Antiphospholipid Syndrome in the United States
Lauren Mathias¹, Aditya Mantha², Kristen Mathias³ and Glenn Ehresmann¹, ¹University of Southern California, Division of Rheumatology, Los Angeles, CA, ²University of Southern California, Department of Medicine, Los Angeles, CA, ³University of Chicago, Department of Medicine, Chicago, IL
Background/Purpose: Antiphospholipid syndrome (APLS) is characterized by arterial and venous thrombosis, often in the setting of an underlying systemic disease. Few studies have described the…
Abstract Number: 1775 • ACR Convergence 2020
Risk Factors for Adverse Pregnancy Outcomes of Women with Positive for Antiphospholipid Antibodies Treated with Conventional Therapies
Hiromi Shimada¹, Risa Wakiya², Mai Mahmound Fahmy Mansour¹, Shusaku Nakashima¹, Mikiya Kato¹, Koichi Sugihara¹, Yusuke Ushio¹, Tomohiro Kameda¹ and Hiroaki Dobashi³, ¹Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kita-gun, Kagawa, Japan, ²Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kagawa, Kagawa, Japan, ³Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Antiphospholipid antibodies induce several obstetric complications including recurrent spontaneous abortion, preterm birth, intrauterine fetal death. EULAR recommendations for antiphospholipid syndrome (APS) indicates low dose…
Abstract Number: 0526 • ACR Convergence 2020
Patient-Reported Outcomes in Antiphospholipid Syndrome
Julia Weiner¹, Kelsey Gockman¹, Jacqueline Madison¹, Yu Zuo², Emily Briceño¹, Vivek Nagaraja³ and Jason Knight², ¹University of Michigan, Ann Arbor, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI
Background/Purpose: PROMIS® (Patient-Reported Outcome Measurement Information System) is a set of person-centered measures that evaluates and monitors the physical, emotional, and social aspects of health.…
Abstract Number: 1792 • ACR Convergence 2020
Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE
Yevgeniya Gartshteyn¹, Roberta Vezza Alexander², John Conklin³, Thierry Dervieux⁴ and Anca Askanase⁵, ¹Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ²Exagen Inc, Vista, CA, ³Exagen Inc., Vista, CA, ⁴Prometheus Biosciences Inc, San Diego, CA, ⁵Columbia University College of Physicians and Surgeons, New York, NY
Background/Purpose: Platelet-bound complement activation products (PC4d), defined as PC4d20 net mean fluorescent intensity [MFI], or a thrombotic risk score that includes PC4d, C3 and anti-phosphatidylserine/prothrombin…
Abstract Number: 0527 • ACR Convergence 2020
Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Israeli Experience
Nancy Agmon-Levin¹, Mark Berman², Liora Harel³, Merav Lidar⁴, Soad Hajyahia¹ and Daphna Paran⁵, ¹Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Scheider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel, Petach Tikva, Israel, ⁴Rheumatology unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Hod Hasharon, Israel, ⁵Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: The clinical manifestations of the antiphospholipid syndrome (APS) are heterogeneous and related to anti-phospholipid antibodies (aPL). There is some evidence that B cells are…
Abstract Number: 0528 • ACR Convergence 2020
The Complex Relationship Between C4b Binding Protein, Warfarin and Antiphospholipid Antibodies
Giorgia Grosso¹, Kerstin Sandholm², Aleksandra Antovic¹, Iva Gunnarsson¹, Agneta Zickert¹, Anna Vikerfors³, Lennart Truedsson⁴, Maria Bruzelius¹, Bo Nilsson⁵, Kristina Nilsson Ekdahl⁵ and Elisabet Svenungsson¹, ¹Karolinska University Hospital, Stockholm, Sweden, ²Linnaeus Center for Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden, ³Swedish Medical Products Agency, Uppsala, Sweden, ⁴Lunds University, Lund, Sweden, ⁵Uppsala University, Uppsala, Sweden
Background/Purpose: C4b Binding Protein (C4BP) is the main inhibitor of the classical complement pathway. Both β2glycoprotein-I (β2GPI), the main antigen in the antiphospholipid syndrome (APS),…
Abstract Number: 0529 • ACR Convergence 2020
A Prospective Study on the Incidence of a First Thrombo-embolic Event in Patients with Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies
Savino Sciascia¹, Massimo Radin¹, Irene Cecchi¹, Daniela Rossi¹ and Dario Roccatello², ¹University of Torino, Torino, Italy, ²S Giovanni Hospital, Univ of Turin, Turin, Italy
Background/Purpose: Prospective data confirming the role of anti-phosphatidylserine/prothrombin antibodies (aPS/PT) in the absence of other aPL tested by β2–glycoprotein I-depend assays are missing.Methods: Since 2015 aPSPT…
Abstract Number: 0530 • ACR Convergence 2020
Pediatric APS: Clinical Features, Therapeutic Interventions, and Damage in a Series of 22 Cases
Jacqueline Madison¹, Kelsey Gockman¹ and Jason Knight², ¹University of Michigan, Ann Arbor, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…
Abstract Number: 0847 • ACR Convergence 2020
Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity
Laurence Magder¹, Daniel Goldman² and Michelle Petri², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: SLE patients with certain immunological markers (i.e., anti-DNA, low complement) are at higher risk of lupus nephritis and those with antiphospholipid antibodies are at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].